Compile Data Set for Download or QSAR
Report error Found 218 Enz. Inhib. hit(s) with all data for entry = 11326
TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607734(US11691962, Compound 1-132)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607732(US11691962, Compound 1-130)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607731(US11691962, Compound 1-129)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607738(US11691962, Compound 1-136)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607737(US11691962, Compound 1-135)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607736(US11691962, Compound 1-134)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607742(US11691962, Compound 1-140)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607740(US11691962, Compound 1-138)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607739(US11691962, Compound 1-137)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607746(US11691962, Compound 1-144)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607745(US11691962, Compound 1-143)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607744(US11691962, Compound 1-142)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607743(US11691962, Compound 1-141)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607718(US11691962, Compound 1-116)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607717(US11691962, Compound 1-115)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607716(US11691962, Compound 1-114)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607715(US11691962, Compound 1-113)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607722(US11691962, Compound 1-120)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607721(US11691962, Compound 1-119)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607720(US11691962, Compound 1-118)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607719(US11691962, Compound 1-117)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607726(US11691962, Compound 1-124)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607725(US11691962, Compound 1-123)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607730(US11691962, Compound 1-128)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607729(US11691962, Compound 1-127)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607727(US11691962, Compound 1-125)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607766(US11691962, Compound 1-164)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607765(US11691962, Compound 1-163)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607764(US11691962, Compound 1-162)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607763(US11691962, Compound 1-161)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607770(US11691962, Compound 1-168)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607769(US11691962, Compound 1-167)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607768(US11691962, Compound 1-166)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607774(US11691962, Compound 1-172)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607777(US11691962, Compound 1-175)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607749(US11691962, Compound 1-147)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607748(US11691962, Compound 1-146)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607747(US11691962, Compound 1-145)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607754(US11691962, Compound 1-152)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607753(US11691962, Compound 1-151)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607752(US11691962, Compound 1-150)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607758(US11691962, Compound 1-156)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607757(US11691962, Compound 1-155)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607756(US11691962, Compound 1-154)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607755(US11691962, Compound 1-153)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607762(US11691962, Compound 1-160)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607761(US11691962, Compound 1-159)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607760(US11691962, Compound 1-158)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607798(US11691962, Compound 1-196)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Exithera Pharmaceuticals

US Patent
LigandPNGBDBM607797(US11691962, Compound 1-195)
Affinity DataIC50: 10nMAssay Description:The ability of compounds of the present invention to inhibit Factor XIa was evaluated by determining the concentration of inhibitor, which resulted i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 218 total ) | Next | Last >>
Jump to: